Contrast media-induced nephropathy following diagnostic and therapeutic cardiac catheterization;Nefropatia induzida pelos meios de contraste radiológico após cateterismo cardíaco diagnóstico e terapêutico

Arquivos Brasileiros de Cardiologia

Volumn 87, Issue 3, 2006, Pages

  Ultramari, Frederico Thomaz ^a,b   Bueno, Ronaldo Da Rocha Loures ^a   Da Cunha, Cláudio Leinig Pereira ^a   De Andrade, Paulo Maurício Pía ^a   Nercolini, Deborah Cristina ^a   Tarastchuk, José Carlos Estival ^a   Faidiga, Alysson Moço ^a   Melnik, Gilberto ^a   Guérios, Ênio Eduardo ^a  

^a HOSPITAL UNIVERSITÁRIO EVANGÉLICO DE CURITIBA   (Brazil)

^b NONE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ADENOSINE RECEPTOR BLOCKING AGENT; ASCORBIC ACID; ATRIAL NATRIURETIC FACTOR; CALCIUM CHANNEL BLOCKING AGENT; CONTRAST MEDIUM; DIURETIC AGENT; DOPAMINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; FENOLDOPAN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HEART CATHETERIZATION; HEMODIALYSIS; HEMODYNAMICS; HOSPITALIZATION; HUMAN; HYDRATION; INCIDENCE; KIDNEY BLOOD FLOW; KIDNEY DISEASE; KIDNEY TUBULE FUNCTION; LIPID PEROXIDATION; MALE; OSMOLARITY; PATHOGENESIS; PROGNOSIS; PROPHYLAXIS; RISK FACTOR; VASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; REVIEW;

CONTRAST MEDIA; FEMALE; HEART CATHETERIZATION; HUMANS; KIDNEY FAILURE, ACUTE; MALE; OSMOLAR CONCENTRATION; PROGNOSIS; RISK FACTORS;

EID: 33750392406     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: None     Document Type: Article

References (134)

1. Berg KJ. Nephrotoxicity related to contrast media. Scand J Urol Nephrol 2000; 34: 317-22.
2. Solomon R. Contrast-medium-induced acute renal failure. Kidney Int 1998; 3: 230-42.
3. Krämer BK, Kammerl M, Schweda F, et al. A primer in radiocontrast-induced nephropathy. Nephrol Dial Transplant 1999; 14: 2830-4.
4. Hou SH, Bushinsky DA, Wish JB, et al. Hospital-acquired renal insufficiency: a prospective study. Am J Med 1983; 74: 243-8.
5. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality: a cohort analysis. JAMA 1996; 275: 1489-94.
6. Gomes VO, Blaya P, Brizolara A, et al. Nefropatia induzida por contraste radiológico em pacientes submetidos a cateterismo cardíaco. Rev Bras Cardiol Invas 2002; 10: 43-9.
7. Morcos SK, Thomsen HS, Webb JA. Contrast-media-induced nephrotoxicity: a consensus report. Eur Radiol 1999; 9: 1602-13.
8. Katzberg RW. Urography into the 21st century: new contrast media, renal handling, imaging characteristics and nephrotoxicity. Radiology 1997; 204: 297-312.
9. Waybill MM, Waybill PN. Contrast media-induced nephrotoxicity: identification of patients at risk and algorithms for prevention. J Vasc Interv Radiol 2001; 12: 3-9.
10. Russo D, Minutolo R, Cianciaruso B, et al. Early effects of contrast media on renal hemodynamics and tubular function in chronic renal failure. J Am Soc Nephrol 1995; 6: 1451-8.
11. Barret BJ. Contrast nephrotoxicity. J Am Soc Nephrol 1994; 5: 125-37.
12. Weisberg LS, Kurnik PB, Kurnik BR. Risk of radiocontrast nephropathy in patients with and without diabetes mellitus. Kidney Int 1994; 45: 259-65.
13. Agmon Y, Peleg H, Greenfield Z, et al. Nitric oxid and prostanoids protect the renal outer medulla from radiocontrast toxicity in the rat. J Clin Invest 1994; 94: 1069-75.
14. Yoshioka T, Fogo A, Beckman JK. Reduced activity of antioxidant enzymes underlies contrast media-induced renal injury in volume depletion. Kidney Int 1992; 41: 1008-15.
15. Katzberg RW, Schulman G, Meggs L, et al. Mechanism of the renal response to contrast medium in dogs: decrease in renal function due to hipertonicity. Invest Radiol 1983; 18: 74-80.
16. Dorph S, Sovak M, Talner LB, et al. Why does kidney size change during IV urography? Invest Radiol 1977; 12: 246-50.
17. Bakris GL, Burnett JC. A role for calcium in radiocontrast reduction in renal hemodynamics. Kidney Int 1985: 27: 465-8.
18. Spielman WS, Thompson CI. A proposed role for adenosine in the regulation of renal hemodynamics and renin release. Am J Physiol 1982; 242: 423-35.
19. Arend LJ, Bakris GL, Burnett JC, et al. Role of intrarenal adenosine in the renal hemodynamic response to contrast media. J Lab Clin Med 1987; 110: 406-11.
20. Simonson MS. Endothelium: multifunctional renal peptides. Physiol Rev 1993; 73: 375-411.
21. Clark BA, Heyman SN, Spokes K, et al. Rise in plasma endothelin produced by radiocontrast agents. J Am Soc Nephrol 1990; 1: 412 (abstract).
22. Heyman SN, Clark BA, Kaiser N, et al. Radiocontrast agents induce endothelin release in vivo and in vitro. J Am Soc Nephrol 1992; 3: 58-65.
23. Margulies KB, McKinley LJ, Burnett JC. Endothelin in human and canine radiocontrast-induced nephropathy. J Vasc Res 1992; 29: 163-4.
24. Oldroyd S, Slee SJ, Haylor J, et al. Role for endothelin in the renal responses to radiocontrast media in the rat. Clin Sci 1994; 87: 427-34.
25. Katzberg RW, Meggs LG, Schulman G, et al. Contrast medium-induced renal vasoconstriction and endogenous vasoconstrictor hormones. Br J Radiol 1982; 55: 266-8.
26. Caldicott WJH, Hollenberg NK, Abrams HL. Characteristics of response of the renal vascular bed to contrast media: evidence for vasoconstriction induced by renin-angiotensin system. Invest Radiol 1970; 5: 539-47.
27. Heyman SN, Reichman J, Brezis M. Pathophysiology of radiocontrast nephropathy. A role for medullary hypoxia. Invest Radiol 1999; 34: 685-91.
28. Brezis M, Heyman SN, Dinour D, et al. Role of nitric oxide in renal medullary oxygenation: studies in isolated and intact rat kidneys. J Clin Invest 1991; 88: 390-5.
29. Pabico RC, Katzberg RW, McKenna BA, et al. Hypertonic contrast medium and the kidney: effects on renal functions in the euvolemic and in the dehydrated dogs. In: Boch PH, Lock EA, eds. Nephrotoxicity. New York, NY: Plenum, 1989; 485-9.
30. Humes HD, Hunt DA, White MD. Direct toxic effect of the radiocontrast agent diatrizoate on renal proximal tubule cells. Am J Physiol 1987; 252: 246-55.
31. Dobrota M, Powell CJ, Holtz E, et al. Biochemical and morphological effects of contrast media on the kidney. Acta Radiol 1995; 36 (Suppl 399): 196-203.
32. Perillie PE, Conn HD. Acute renal failure after intravenous pielography in plasma cell myeloma. JAMA 1958; 167: 2186-9.
33. Meyers GH, Witten DM. Acute renal failure after excretory urography in multiple myeloma. Am J Roentgenol Rad Ther Nucl Med 1971; 113: 583-8.
34. Harkonen S, Kjelstrand C. Contrast nephropathy. Am J Nephrol 1981; 7: 69-77.
35. Tejler L, Almén T, Holtas S. Proteinuria following nephroangiography. I. Clinical experiences. Acta Radiol Diagn 1980; 21: 491-4.
36. Holtas S, Almén T, Hellsten S, et al. Proteinuria following nephroangiography. VI. Comparision between metrizoate and metrizamidein man. Acta Radiol Diagn 1980; 21: 491-4.
37. Parvez Z, Romanurstly S, Patel NB, et al. Enzyme markers of contrast media-induced renal failure. Invest Radiol 1990; 25: 133-4.
38. Naidu SG, Lee FT. Contrast nephrotoxicity: predictive value of urinary enzyme markers in a rat model. Acad Radiol 1994; 1: 3-9.
39. Bakris GL, Lass N, Gaber AO, et al. Radiocontrast medium-induced declines in renal function: a role for oxygen radicals. Am J Physiol 1990; 258: 115-20.
40. Hanss BG, Valencia SH, Shah SV, et al. The iron chelator deferoxamine prevents contrast media induced acute renal failure in the rabbit. J Am Soc Nephrol 1990; 1: 612.
41. Davidson CJ, Hlatky M, Morris KG, et al. Cardiovascular and renal toxicity of a nonionic radiographic contrast agent after cardiac catheterization: a prospective trial. Ann Intern Med 1989; 110: 119-24.
42. Nash K, Hafeez A, Abrinko P, et al. Hospital-acquired renal insufficiency. J Am Soc Nephrol 1996; 7: 1376 (abstract).
43. Manske CL, Sprafka JM, Strony JH, et al. Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am J Med 1990; 89: 615-20.
44. Lautin EM, Freeman NJ, Schoenfeld AH, et al. Radiocontrast-associated renal dysfunction: incidence and risk factors. Am J Roentgenol 1991; 157: 49-58.
45. Rich MW, Crecelius CA. Incidence, risk factors, and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age or older: a prospective study. Arch Intern Med 1990; 150: 1237-42.
46. Parfrey PS, Griffiths SM, Barrett BJ, et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both: a prospective controlled study. N Engl J Med 1989; 320: 143-9.
47. Bartholomew BA, Harjai KJ, Dukkipati S, et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol 2004; 93: 1515-19.
48. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002; 105: 2259-64.
49. McCullough PA, Wolyn R, Rocher LL, et al. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997; 103: 368-75.
50. Rudnick MR, Goldfarb S, Wexler L, et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial: the lohexol Cooperative Study. Kidney Int 1995; 47: 254-61.
51. Barrett BJ, Parfrey PS, Vavasour HM, et al. Contrast nephropathy in patients with impaired renal function: high versus low osmolar media. Kidney Int 1992; 41: 1274-9.
52. D'Elia JA, Gleason RE, Alday M, et al. Nephrotoxicity from angiographic contrast material. A prospective study. Am J Med 1982; 72: 719-25.
53. Taliercio CP, Vlietstra RE, Fisher LD, et al. Risks for renal dysfunction with cardiac angiography. Ann Intern Med 1986; 104: 501-504.
54. Cigarroa RG, Lange RA, Williams RH, et al. Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am J Med 1989; 86: 649-52.
55. Weinrauch LA, Healy RW, Leland OS, et al. Coronary angiography and acute renal failure in diabetic azotemic nephropathy. Ann Intern Med 1977; 86: 56-9.
56. Barrett BJ, Carlisle EJ. Metaanalysisof the relative nephrotoxicity of high and low- osmolality iodinated contrast media. Radiology 1993; 188: 171-8.
57. Hill JA, Winniford M, Van Fossen DB, et al. Nephrotoxicity following cardiac angiography: a randomized double-blind multicenter trial of ionic and nonionic contrast media in 1194 patients. Circulation 1991; 84: 11-33.
58. Taliercio CP, Vlietstra RE, Ilstrup DM, et al. A randomized comparison of the nephrotoxicity of iopamidol and diatrizoate in high risk patients undergoing cardiac angiography. J Am Coll Cardiol 1991; 17: 384-90.
59. Harris KG, Smith TP, Cragg HA, et al. Nephrotoxicity from contrast material in renal insufficiency. Radiology 1991; 179: 849-52.
60. Schwab SJ, Hlatky MA, Pieper KS, et al. Contrast nephrotoxicity: a randomized controlled trial of a nonionic and an ionic radiographic contrast agent. N Engl J Med 1989; 320: 149-53.
61. Grynne B, Nossen JØ, Bolstad B, et al. Main results of the first comparative studies on Visipaque. Acta Radiol 1995;36 (Suppl 399): 265-70.
62. Clauss W, Dinger J, Meissner C. Renal tolerance of iotrolan 280 - a meta-analysis of 14 double-blind studies. Eur Radiol 1995; 5: 79-84.
63. Davidson CJ, Laskey WK, Hermilller JB, et al. Randomized trial of contrast media utilization in high-risk PTCA: the COURT trial. Circulation 2000; 101: 2172-7.
64. Aspelin P, Aubry P, Fransson SG, et al. Nephrotoxic Effects in High-Risk Patients Undergoing Angiography. N Engl J Med 2003; 348: 491-9.
65. Chalmers N, Jackson RW. Comparison of iodixanol and iohexol in renal impairment. Br J Radiol 1999; 72: 701-703.
66. Heyman SN, Brezis M, Greenfeld Z, et al. Protective role of furosemide and saline in radiocontrast-induced acute renal failure in the rat. Am J Kidney Dis 1989; 14: 377-85.
67. McCarthy CS, Becker JA. Multiple mieloma and contrast media. Radiology 1992; 183: 519-21.
68. Gruberg L, Mintz GS, Mehran R, et al. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol 2000; 36: 1542-8.
69. Moore RD, Steinberg EP, Powe NR, et al. Nephrotoxicity of high-osmolality versus low-osmolality contrast media: randomized clinical trial. Radiology 1992; 182: 649-55.
70. Mason RA, Arbeit LA, Giron F. Renal dysfunction after arteriography. JAMA 1985; 253: 1001-04.
71. Gomes AS, Baker JD, Martin-Paradero V, et al. Acute renal dysfunction after major arteriography. Am J Roentgenol 1985; 145: 1249-53.
72. Kennedy JW, Registry Committee of the Society for Cardiac Angiography. Complications associated with cardiac catheterization and angiography. Cathet Cardiovasc Diagn 1982; 8: 5-11.
73. Johnson LW, Lozner EC, Johnson S, et al. Coronary arteriography: 1984-1987: a report of the registry of the Society for Cardiac Angiography and Interventions, I: results and complications. Cathet Cardiovasc Diagn 1989; 17: 5-10.
74. Fang LST, Sirota RA, Ebert TH, et al. Low fractional excretion of sodium with contrast media induced acute renal failure. Arch Intern Med 1980; 140: 531-3.
75. Porter GA. Radiocontrast-induced nephropathy. Nephrol Dial Transplant 1994; 9: 146-56.
76. Rudnick MR, Berns JS, Cohen RM, et al. Nephrotoxic risks on renal angiography: contrast media-associated nephrotoxicity and atheroembolism - a critical review. Am J Kidney Dis 1994; 24: 713-27.
77. Safirstein R, Andrade L, Vieira JM. Acetylcysteine and nephrotoxic effects of radiographic contrast agents: a new use for an old drug. N Engl J Med 2000; 343: 209-12.
78. Jones AL, Haynes W, MacGilchrist AJ, et al. N-acetylcysteine is a potent peripheral vasodilator. Gut 1994, 35(Suppl 5): 10 (abstract).
79. Briguori C, Manganelli F, Scarpato P, et al. Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol 2002; 40: 298-303.
80. Fung JW, Szeto CC, Chan WW, et al. Effect of N-acetylcysteine for prevention of contrast nephropathy in patients with moderate to severe renal insufficiency: a randomized trial. Am J Kidney Dis 2004; 43: 801-08.
81. Webb JG, Pate GE, Humphries KH, et al. A randomized controlled trial of intravenous n-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect. Am Heart J 2004; 148: 422-9.
82. Durham JD, Caputo C, Dokko J, et al. A randomized controlled trial of n-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int 2002; 62: 2202-07.
83. Goldenberg I, Shechter M, Matetzky S, et al. Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography: a randomized controlled trial and review of the current literature. Eur Heart J 2004; 25: 212-18.
84. Gomes VO, Figueredo CEP, Caramori P, et al. N-acetylcysteine does not prevent contrast induced nephropathy after cardiac catheterization with an ionic low osmolality contrast medium: a multicentre clinical trial. Heart 2005; 91: 774-8.
85. Alonso A, Lau J, Jaber BL, et al. Prevention of radiocontrast nephropathy with n-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials. Am J Kidney Dis 2004; 43: 1-9.
86. Misra D, Leibowitz K, Gowda RM, et al. Role of n-acetylcysteine in prevention of contrast-induced nephropathy after cardiovascular procedures: a meta-analysis. Clin Cardiol 2004; 27: 607-10.
87. Birck R, Krzossok S, Markowetz F, et al. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet 2003; 362: 598-603.
88. Isenbarger DW, Kent SM, O'Malley PG. Meta-analysis of randomized clinical trials on the usefulness of acetylcysteine for prevention of contrast nephropathy. Am J Cardiol 2003; 92: 1454-8.
89. Briguori C, Colombo A, Violante A, et al. Standard vs. double dose of n-acetylcysteine to prevent contrast agent associated nephrotoxicity. Eur Heart J 2004; 25: 206-211.
90. Baker CSR, Wragg A, Kumar S, et al. A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Cardiol 2003; 41: 2114-18.
91. Ochoa A, Pellizzon G, Addala S, et al. Abbreviated dosing of n-acetylcysteine prevents contrast-induced nephropathy after elective and urgent coronary angiography and intervention. J Interv Cardiol 2004; 17: 159-65.
92. Spargias K, Alexopoulos E, Kyrzopoulos S, et al. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation 2004; 110: 1-6.
93. Huber W, Schipek C, Ilgmann K, et al. Effectiveness of theophylline prophylaxis of renal impairment after coronary angiography in patients with chronic renal insufficiency. Am J Cardiol 2003; 91: 1157-62.
94. Erley CM, Duda SH, Schlepckow S, et al. Adenosine antagonist theophylline prevents the reduction of glomerular filtration rate after contrast media application. Kidney Int 1994; 45: 1425-31.
95. Abizaid AS, Clark CE, Mintz GS, et al. Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency. Am J Cardiol 1999; 83: 260-63.
96. Shammas NW, Kapalis MJ, Harris M, et al. Aminophylline does not protect against radiocontrast nephropathy in patients undergoing percutaneous angiographic procedures. J Invasive Cardiol 2001; 13: 738-40.
97. Fujise K, Stacy L, Beck P, et al. Differential effects of endothelin receptor activation on cyclic flow variations in rat mesenteric arteries. Circulation 1997; 93: 1860.
98. Seo B, Oemar BS, Siebenmann R, et al. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation 1994; 89: 1203-08.
99. Pollock DM, Polakowski JS, Wegner CD, et al. Beneficial effect of ETA receptor blockade in a rat model of radiocontrast-induced nephropathy. Renal Failure 1997; 19: 753-61.
100. Bird JE, Giancarli MR, Megill JR, et al. Effects of endothelin in radiocontrast-induced nephropathy in rats are mediated through endothelin-A receptors. J Am Soc Nephrol 1996; 7: 1153-7.
101. Wang A, Holcslaw T, Bashore TM, et al. Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism. Kidney Int 2000; 57: 1675-80.
102. Wilfling M, Kampf D, Jun MS, et al. Nitrendipine and nephrotoxicity of non-ionic contrast media: a randomized controlled clinical trial. J Am Soc Nephrol 1995; 6: 671.
103. Neumayer HH, Junge W, Kufner A, et al. Prevention of radiocontrast media-induced nephrotoxicity by the calcium channel blocker nitrendipine: a prospective randomized controlled trial. Nephrol Dial Transplant 1989; 4: 1030-36.
104. Carraro M, Mancini W, Artero M, et al. Dose effect of nitrendipine on urinary enzymes and microproteinsfollowing non-ionic radiocontrast administration. Nephrol Dial Transplant 1996; 11: 444-8.
105. Khoury Z, Schlicht JR, Como J, et al. The effect of prophylactic nifedipine on renal function in patients administered contrast media. Pharmacotherapy 1995; 15: 59-65.
106. Miller HI, Dascalu A, Rassin TA, el al. Effects of an acute dose of I-arginine during coronary angiography in patients with chronic renal failure: a randomized, parallel, double-blind clinical trial. Am J Nephrol 2003; 23: 91-5.
107. Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 2004; 291: 2328-34.
108. Solomon R, Werner C, Mann D, et al. Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994; 331: 1416-20.
109. Weinstein J, Heyman S, Brezis M. Potential deleterious effect of furosemide in radiocontrast nephropathy. Nephron 1992; 62: 413-15.
110. Stevens MA, McCullough PA, Tobin KJ, et al. A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy results of the P.R.I.N.C.E. study. J Am Coll Cardiol 1999; 33: 403-11.
111. Gare M, Haviv YS, Ben-Yehuda A, et al. The renal effect of low-dose dopamine in high-risk patients undergoing coronary angiography. J Am Coll Cardiol 1999; 34: 1682-8.
112. Hall KA, Wong RW, Hunter GC, et al. Contrast-induced nephropathy: the effects of vasodilator therapy. J Surg Res 1992; 53: 317-20.
113. Hans B, Hans SS, Mittal VK, et al. Renal functional response to dopamine during and after arteriography in patients with chronic renal insufficiency. Radiology 1990; 176: 651-4.
114. Mathur VS, Ellis D, Fellmann J, et al. Therapeutics for hypertensive urgencies and emergencies - fenoldopan: a novel systemic and renal vasodilator. Cardiovasc Intervent Radiol 1998; 1: 43-53.
115. Tumlin JA, Wang A, Murray PT, et al. Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy. Am Heart J 2002; 143: 894-903.
116. Kini AS, Mitre CA, Kim M, et al. A protocol for prevention of radiographic contrast nephropathy during percutaneous coronary intervention: effect of selective dopamine receptor agonist fenoldopam. Catheter Cardiovasc Interv 2002; 55: 169-73.
117. Stone GW, McCullough PA, Tumlin JA, et al. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA 2003; 290: 2284-91.
118. Briguori C, Colombo A, Airoldi F, et al. N-acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity. J Am Coll Cardiol 2004; 44: 762-5.
119. Allaqaband S, Tumuluri R, Malik AM, et al. Prospective randomized study of n-acetylcysteine, fenoldopam and saline for prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc Interv 2002; 57: 279-83.
120. Sterner G, Frennby B, Kurkus J, et al. Does post-angiographic hemodialysis reduce the risk for contrast medium nephropathy? Scand J Urol Nephrol 2000; 34: 324-7.
121. Lehnert T, Keller E, Gondolf K, et al. Effect of hemodialysis after contrast medium administration in patients with severe renal insufficiency. Nephrol Dial Transplant 1998; 13: 358-62.
122. Huber W, Jeschke B, Kreymann B, et al. Hemodialysis for the prevention of contrast-induced nephropathy: outcome of 31 patients with severely impaired renal function, comparison with patients at similar risk and review. Invest Radiol 2002; 37: 471-81.
123. Frank H, Werner D, Lorusso V, et al. Simultaneous hemodialysis during coronary angiography fails to prevent radiocontrast-induced nephropathy in chronic renal failure. Clin Nephrol 2003; 60: 176-82.
124. Vogt B, Ferrari P, Schönholzer C, et al. Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful. Am J Med 2001; 111: 692-8.
125. Marenzi G, Marana I, Lauri G, et al. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med 2003; 349: 1333-40.
126. Mueller C, Buerkle G, Buettner H, et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002; 162: 329-36.
127. Kurnik BR, Allgren RL, Genter FC, et al. Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy. Am J Kidney Dis 1998; 31: 674-80.
128. Koch JA, Plum J, Grabensee B, et al. Prostaglandin E1: a new agent for the prevention of renal dysfunction in high risk patients caused by radiocontrast media? Nephrol Dial Transplant 2000; 15: 43-9.
129. Tommaso CL. Contrast-induced nephrotoxicity in patients undergoing cardiac catheterization. Cath Cardiovasc Diagn 1994; 31: 316-21.
130. Freeman RV, O'Donnell M, Share D, et al. Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose. Am J Cardiol 2002; 90: 1068-1073.
131. Porter GA. Contrast-associated nephropathy. Am J Cardiol 1989; 64: 22-26.
132. Fenves AZ, Allgren RL. Radiocontrast dye-induced acute tubular necrosis: atrial natriuretic peptide versus placebo. J Am Soc Nephrol 1995; 6: 463 (abstract).
133. Shlipak MG, Heidenreich PA, Noguchi H, et al. Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med 2002; 137: 555-62.
134. Sadeghi HM, Stone GW, Grines CL, et al. Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. Circulation 2003; 108: 2769-75.